*EMBARGOED All research presented at the 2022 ACG Annual Scientific Meeting and Postgraduate Course is strictly embargoed until Sunday, October 23, 2022, at 12:00 pm EDT.
Tuesday, October 25, 2022 | 3:15 PM – 3:25 PM ET | Location: Hall C2
Author Insight from Rishika Chugh, MD, University of California San Francisco
What’s new here and important for clinicians?
Data from the PIANO registry has demonstrated the safety of biologics and thiopurines but with small numbers for vedolizumab and ustekinumab.
- There remain safety concerns surrounding ustekinumab and vedolizumab due to a lack of and conflicting available data.
- We found no increase in pregnancy and infant related complications with ustekinumab or vedolizumab compared with no exposure, TNFs, thiopurines and combination TNF with thiopurines.
- Ustekinumab was associated with lower rates of preterm birth and C-section.
- No signal was found for increased placental events with either therapy.
- Continuation of UST and VDZ during pregnancy is recommended.
What do patients need to know?
- Vedolizumab and ustekinumab can be continued throughout pregnancy
- There is no increased risk of adverse pregnancy or infant related outcomes
Read the Abstract
Rishika Chugh, MD, University of California San Francisco
rishika.chugh [at] ucsf.edu
Media Interview Requests
To arrange an interview with any ACG experts or abstract authors, please contact Becky Abel of ACG via email at mediaonly [at] gi.org or by phone at 301-263-9000.